liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Valuations as Mediators Between Science and the Market: How Economic Assumptions Shape Pharmaceutical Trial Designs
Linköping University, Department of Thematic Studies, Technology and Social Change. Linköping University, Faculty of Arts and Sciences.ORCID iD: 0000-0002-6074-6088
Uppsala University, Sweden.
2017 (English)In: Science as Culture, ISSN 0950-5431, E-ISSN 1470-1189, Vol. 26, no 4, p. 529-554Article in journal (Refereed) Published
Abstract [en]

How can economic assumptions be present in the heart of commercially driven drug development research? Such assumptions underpin industry-based bio-statistical discussions around a new pharmaceutical trial design, the compound finder. This example illustrates several ways in which trials might be designed and situated in the larger setting of interlinked valuation practices central to the development, distribution, and use of pharmaceuticals. It shows how economic assumptions and considerations can be differently entwined with endeavors to produce knowledge. Different trial designs may further differ in what knowledge they produce. Adaptive design trials (ADTs), of which the compound finder is one kind, share the feature that they might be the object of thousands of simulations to specify the design taking many different kinds of considerations into account. These considerations include several economic aspects such as trial costs and assumptions about the future market. ADTs will likely continue to become more common in the years to come, even if the future for the specific compound finder trial design is uncertain. Yet, the continued rise in importance of ADTs means a further intimate entwining of economic assumptions into the specification of trial designs. This will be consequential for what knowledge is produced as well as where and how treatments are assessed.

Place, publisher, year, edition, pages
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD , 2017. Vol. 26, no 4, p. 529-554
Keywords [en]
drug development; economic assumptions; trial design; medical research; valuation
National Category
Social Sciences Interdisciplinary
Identifiers
URN: urn:nbn:se:liu:diva-143380DOI: 10.1080/09505431.2017.1374940ISI: 000415751700009OAI: oai:DiVA.org:liu-143380DiVA, id: diva2:1162723
Note

Funding Agencies|Riksbankens Jubileumsfond [P11-0034:1]

Available from: 2017-12-05 Created: 2017-12-05 Last updated: 2018-01-13

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Search in DiVA

By author/editor
Helgesson, Claes-Fredrik
By organisation
Technology and Social ChangeFaculty of Arts and Sciences
In the same journal
Science as Culture
Social Sciences Interdisciplinary

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 71 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf